Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 309

1.

Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment.

Fleisher AS, Sowell BB, Taylor C, Gamst AC, Petersen RC, Thal LJ; Alzheimer's Disease Cooperative Study.

Neurology. 2007 May 8;68(19):1588-95. Epub 2007 Feb 7.

PMID:
17287448
2.

Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment.

Fleisher AS, Sun S, Taylor C, Ward CP, Gamst AC, Petersen RC, Jack CR Jr, Aisen PS, Thal LJ.

Neurology. 2008 Jan 15;70(3):191-9. doi: 10.1212/01.wnl.0000287091.57376.65.

PMID:
18195264
3.

Influence of apolipoprotein E varepsilon4 on rates of cognitive and functional decline in mild cognitive impairment.

Whitehair DC, Sherzai A, Emond J, Raman R, Aisen PS, Petersen RC, Fleisher AS; Alzheimer's Disease Cooperative Study.

Alzheimers Dement. 2010 Sep;6(5):412-9. doi: 10.1016/j.jalz.2009.12.003.

4.

Periventricular white matter hyperintensities increase the likelihood of progression from amnestic mild cognitive impairment to dementia.

van Straaten EC, Harvey D, Scheltens P, Barkhof F, Petersen RC, Thal LJ, Jack CR Jr, DeCarli C; Alzheimer's Disease Cooperative Study Group.

J Neurol. 2008 Sep;255(9):1302-8. doi: 10.1007/s00415-008-0874-y. Epub 2008 Sep 25.

5.

Donepezil delays progression to AD in MCI subjects with depressive symptoms.

Lu PH, Edland SD, Teng E, Tingus K, Petersen RC, Cummings JL; Alzheimer's Disease Cooperative Study Group.

Neurology. 2009 Jun 16;72(24):2115-21. doi: 10.1212/WNL.0b013e3181aa52d3.

6.

Donepezil versus vitamin E in Alzheimer's disease: Part 2: mild versus moderate-severe Alzheimer's disease.

Onofrj M, Thomas A, Luciano AL, Iacono D, Di Rollo A, D'Andreamatteo G, Di Iorio A.

Clin Neuropharmacol. 2002 Jul-Aug;25(4):207-15.

PMID:
12151908
7.

APOE-ɛ4 Carrier Status and Donepezil Response in Patients with Alzheimer's Disease.

Waring JF, Tang Q, Robieson WZ, King DP, Das U, Dubow J, Dutta S, Marek GJ, Gault LM.

J Alzheimers Dis. 2015;47(1):137-48. doi: 10.3233/JAD-142589.

8.

Vitamin E and donepezil for the treatment of mild cognitive impairment.

Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ; Alzheimer's Disease Cooperative Study Group.

N Engl J Med. 2005 Jun 9;352(23):2379-88. Epub 2005 Apr 13.

9.

Characteristics and performance of a modified version of the ADCS-CGIC CIBIC+ for mild cognitive impairment clinical trials.

Schneider LS, Raman R, Schmitt FA, Doody RS, Insel P, Clark CM, Morris JC, Reisberg B, Petersen RC, Ferris SH.

Alzheimer Dis Assoc Disord. 2009 Jul-Sep;23(3):260-7. doi: 10.1097/WAD.0b013e31819cb760.

10.

The importance of Alzheimer disease assessment scale-cognitive part in predicting progress for amnestic mild cognitive impairment to Alzheimer disease.

Rozzini L, Vicini Chilovi B, Bertoletti E, Conti M, Delrio I, Trabucchi M, Padovani A.

J Geriatr Psychiatry Neurol. 2008 Dec;21(4):261-7. doi: 10.1177/0891988708324940.

PMID:
19017783
11.

Adding delayed recall to the Alzheimer Disease Assessment Scale is useful in studies of mild cognitive impairment but not Alzheimer disease.

Sano M, Raman R, Emond J, Thomas RG, Petersen R, Schneider LS, Aisen PS.

Alzheimer Dis Assoc Disord. 2011 Apr-Jun;25(2):122-7. doi: 10.1097/WAD.0b013e3181f883b7.

12.

Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia.

Yu P, Dean RA, Hall SD, Qi Y, Sethuraman G, Willis BA, Siemers ER, Martenyi F, Tauscher JT, Schwarz AJ.

J Alzheimers Dis. 2012;32(2):373-85. doi: 10.3233/JAD-2012-120832.

PMID:
22796873
13.

Telephone screening for amnestic mild cognitive impairment.

Lines CR, McCarroll KA, Lipton RB, Block GA; Prevention of Alzheimer's In Society's Elderly Study Group.

Neurology. 2003 Jan 28;60(2):261-6.

PMID:
12552041
14.

Amnestic syndrome of the medial temporal type identifies prodromal AD: a longitudinal study.

Sarazin M, Berr C, De Rotrou J, Fabrigoule C, Pasquier F, Legrain S, Michel B, Puel M, Volteau M, Touchon J, Verny M, Dubois B.

Neurology. 2007 Nov 6;69(19):1859-67. Erratum in: Neurology. 2008 May 20;70(21):2016.

PMID:
17984454
15.

Effect of ninjin'yoeito, a Kampo (traditional Japanese) medicine, on cognitive impairment and depression in patients with Alzheimer's disease: 2 years of observation.

Kudoh C, Arita R, Honda M, Kishi T, Komatsu Y, Asou H, Mimura M.

Psychogeriatrics. 2016 Mar;16(2):85-92. doi: 10.1111/psyg.12125. Epub 2015 Apr 27.

PMID:
25918972
16.

Cognitive predictors of donepezil therapy response in Alzheimer disease.

Saumier D, Murtha S, Bergman H, Phillips N, Whitehead V, Chertkow H.

Dement Geriatr Cogn Disord. 2007;24(1):28-35. Epub 2007 May 10.

17.

The hard Test Your Memory. Evaluation of a short cognitive test to detect mild Alzheimer's disease and amnestic mild cognitive impairment.

Brown JM, Wiggins J, Dong H, Harvey R, Richardson F, Hunter K, Dawson K, Parker RA.

Int J Geriatr Psychiatry. 2014 Mar;29(3):272-80. doi: 10.1002/gps.4005. Epub 2013 Aug 8.

PMID:
23929807
18.

Association Between Olfactory Dysfunction and Amnestic Mild Cognitive Impairment and Alzheimer Disease Dementia.

Roberts RO, Christianson TJ, Kremers WK, Mielke MM, Machulda MM, Vassilaki M, Alhurani RE, Geda YE, Knopman DS, Petersen RC.

JAMA Neurol. 2016 Jan;73(1):93-101. doi: 10.1001/jamaneurol.2015.2952. Erratum in: JAMA Neurol. 2016 Apr;73(4):481.

19.

Lexical semantic memory in amnestic mild cognitive impairment and mild Alzheimer's disease.

Balthazar ML, Martinelli JE, Cendes F, Damasceno BP.

Arq Neuropsiquiatr. 2007 Sep;65(3A):619-22.

20.

Efficacy of donepezil in mild cognitive impairment: a randomized placebo-controlled trial.

Salloway S, Ferris S, Kluger A, Goldman R, Griesing T, Kumar D, Richardson S; Donepezil 401 Study Group.

Neurology. 2004 Aug 24;63(4):651-7.

PMID:
15326237

Supplemental Content

Support Center